Navigation Links
New Analysis Finds Bioidentical Hormones Safer Than Standard Hormone Replacement Therapy

Comprehensive review demonstrates bioidentical hormones are superior to synthetic HRT with greater cardiovascular benefits and reduced risk of breast cancer

TORRANCE, Calif., Feb. 23 /PRNewswire/ -- The most comprehensive analysis to date, published in the Postgraduate Medical Journal, a leading peer-reviewed publication for practicing clinicians, showed that bioidentical hormones are associated with reduced health risks and are more efficacious than their synthetic counterparts. Conducted by a leading expert in hormone replacement, Kent Holtorf, M.D., medical director of the Holtorf Medical Group in Torrance, California, the paper reviewed and evaluated results from more than 200 physiological and clinical studies. It demonstrated that bioidentical hormone replacement therapy is both more effective and has greater health benefits for women suffering with symptoms of menopause than hormone replacement therapy with synthetic hormones. Synthetic forms of hormone replacement therapy prescribe substances such as Premarin, Provera and Prempro and present real health risks with increased risks of breast cancer, stroke and heart attack.

"Many physicians and so-called experts state that there is no evidence that bioidentical hormones are safer than synthetic HRT. A thorough review of the medical literature, however, clearly supports the claim that bioidentical hormones have some distinctly different, often opposite, physiological effects to those of their synthetic hormones," said Dr. Holtorf, whose practice treats more than 7,000 patients each year. "The medical literature demonstrates that bioidentical hormone replacement therapy is highly effective and carries a reduced, rather than an increased risk of breast cancer and cardiovascular disease."

The review also showed that patients undergoing bioidentical HRT were less likely to experience sleep problems, anxiety, depression and cognitive effects - common side effects of synthetic hormones and are associated with a reduced risk for breast cancer and superior cardiovascular protection.

"While larger, randomized clinical studies are needed, the review of current medical literature demonstrates that bioidentical hormones are a safer, highly effective option for women, and any physician that is practicing evidence-based medicine should be using bioidentical hormone replacement for their patients," said Dr. Holtorf.

Synthetic HRT preparations, which are the most commonly prescribed method of HRT in the United States, are comprised of pregnant horse hormones that are not found in the human body or synthetic hormones that have physiologic effects that mimic or mirror the natural estrogen or progesterone effects in the body. In contrast, bioidentical hormone replacement contains molecules that are exact replicas of the endogenous estrogens and progesterone found in the body and, as such, have distinctly different physiological effects than their synthetic counterparts.

The Holtorf Medical Group is one of the leading authorities on hormone replacement and has been educating patients on the superiority and safety of natural hormones versus synthetic for many years. Dr. Holtorf is available to discuss the FDA's move to halt the use of bioidentical hormones while promoting synthetic hormone therapy, and why discouraging healthcare professionals from using this treatment threatens the health of women everywhere. In addition, Dr. Holtorf can dispel the common misconceptions associated with bioidentical hormone treatment and discuss the significant health benefits patients can expect from this treatment compared to synthetic versions of HRT. For more information or for a copy of the study go to

SOURCE The Holtorf Medical Group
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. BioNanomatrix Announces Issuance of Key Nanofluidics Patent Enabling Single Molecule Whole Genome Analysis
2. SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System
3. Topline Findings from Comparative Analysis of INVEGA(TM) and Quetiapine in Schizophrenia to be Postered at the 20th Annual U.S. Psychiatric and Mental Health Congress
4. Massive reanalysis of genome data solves case of the lethal genes
5. ARRIVE Registry Analysis Demonstrates Continued Safety and Efficacy of TAXUS(R) Stent in Complex Real-World Patients
6. Gene Codes Corporation Announces Version 4.8 of Sequencher Software for DNA Sequence Assembly & Analysis
7. Pharsights Reporting and Analysis Services Business Reaches Quality Assurance Milestone
8. Center for Molecular Medicine Selected to Provide DNA Analysis for Childrens Oncology Group Leukemia Study
9. Credit-card-sized platform for volatile compound analysis CAREER project goal
10. New Glycobiology Analysis Manual 2nd Edition Provides Valuable Resource for Novices and Experts in the Field
11. Pharsights Reporting and Analysis Services Business Unit to Leverage New Validated Data Management System
Post Your Comments:
(Date:6/24/2016)... June 24, 2016  Regular discussions on a range of ... between the two entities said Poloz. Speaking at ... Ottawa , he pointed to the country,s inflation target, ... government. "In certain ... institutions have common economic goals, why not sit down and ...
(Date:6/24/2016)... ... ... Researchers at the Universita Politecnica delle Marche in Ancona combed medical journal ... Their findings are the subject of a new article on the Surviving Mesothelioma website. ... the blood, lung fluid or tissue of mesothelioma patients that can help point doctors ...
(Date:6/23/2016)... 23, 2016   Boston Biomedical , an ... designed to target cancer stemness pathways, announced that ... Orphan Drug Designation from the U.S. Food and ... cancer, including gastroesophageal junction (GEJ) cancer. Napabucasin is ... inhibit cancer stemness pathways by targeting STAT3, and ...
(Date:6/23/2016)... HOUSTON , June 23, 2016 ... agreement with the Cy-Fair Sports Association to serve ... of the agreement, Houston Methodist Willowbrook will provide ... education and connectivity with association coaches, volunteers, athletes ... partner with the Cy-Fair Sports Association and to ...
Breaking Biology Technology:
(Date:4/28/2016)... First quarter 2016:   , Revenues amounted ... quarter of 2015 The gross margin was 49% (27) ... the operating margin was 40% (-13) Earnings per share ... operations was SEK 249.9 M (21.2) , Outlook   ... M. The operating margin for 2016 is estimated to ...
(Date:4/15/2016)...  A new partnership announced today will help ... in a fraction of the time it takes ... life insurance policies to consumers without requiring inconvenient ... Diagnostics, rapid testing (A1C, Cotinine and HIV) and ... weight, pulse, BMI, and activity data) available at ...
(Date:3/31/2016)... 2016   LegacyXChange, ... "Company") LegacyXChange is excited to release its ... to be launched online site for trading 100% guaranteed ... will also provide potential shareholders a sense of the ... an industry that is notorious for fraud. The video ...
Breaking Biology News(10 mins):